Dyslipidemia is common in patients with metabolic dysfunction associated steatotic liver disease (MASLD), characterised by elevated apolipoprotein (apo) B‐containing lipoproteins that are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD) [1]. This evidence concerns the gene APOB and metabolic dysfunction-associated steatotic liver disease.